Literature DB >> 34413502

Prostate cancer screening: a new way forward or another false start?

Peter C Albertsen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34413502     DOI： 10.1038/s41585-021-00513-w

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  MRI-Targeted or Standard Biopsy in Prostate Cancer Screening.

Authors:  Martin Eklund; Fredrik Jäderling; Andrea Discacciati; Martin Bergman; Magnus Annerstedt; Markus Aly; Axel Glaessgen; Stefan Carlsson; Henrik Grönberg; Tobias Nordström
Journal:  N Engl J Med       Date:  2021-07-09       Impact factor: 91.245

2.  The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening.

Authors:  Sarah Benafif; Holly Ni Raghallaigh; Eva McGrowder; Edward J Saunders; Mark N Brook; Sibel Saya; Reshma Rageevakumar; Sarah Wakerell; Denzil James; Anthony Chamberlain; Natalie Taylor; Matthew Hogben; Barbara Benton; Lucia D'Mello; Kathryn Myhill; Christos Mikropoulos; Hywel Bowen-Perkins; Imran Rafi; Michelle Ferris; Andre Beattie; Shophia Kuganolipava; Tamsin Sevenoaks; Juliet Bower; Pardeep Kumar; Steven Hazell; Nandita M deSouza; Antonis Antoniou; Elizabeth Bancroft; Zsofia Kote-Jarai; Rosalind Eeles
Journal:  BJU Int       Date:  2021-08-15       Impact factor: 5.969
  2 in total
  2 in total

1.  Oncogenic ACSM1 in prostate cancer is through metabolic and extracellular matrix-receptor interaction signaling pathways.

Authors:  Yongchen Guo; Chunna Ren; Wentao Huang; Wancai Yang; Yonghua Bao
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

Review 2.  Clinical Significance of Hepsin and Underlying Signaling Pathways in Prostate Cancer.

Authors:  Lucy Lu; Adam Cole; Dan Huang; Qiang Wang; Zhongming Guo; Wancai Yang; Jim Lu
Journal:  Biomolecules       Date:  2022-01-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.